Key facts
- This page summarizes Kenneth Erland Johnson's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Feb 2025, 19:39.
Kenneth Erland Johnson - 31 Jan 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)
- Reporting relationship
- Senior Vice President, Global Development and Medical Affairs
- Issuer ticker
- XERS
- Reported as of
- 31 Jan 2025
- Net transaction value
- -$147,092
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2025, 19:39:11 UTC
- Prior SEC filing
- 07 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Beth Hecht, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kenneth Erland Johnson filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 03 Feb 2025.
Change
- Previous filing in this sequence was filed on 07 Jan 2025.
- Current net transaction value: -$147,092.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XERS
transaction
Common Stock
Tax liability
- Transaction value
- $55,095
- Shares
- -15,476
- Change %
- -4.3%
- Price
- $3.56
- Shares after
- 346,288
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
XERS
transaction
Common Stock
Tax liability
- Transaction value
- $91,998
- Shares
- -25,842
- Change %
- -7.5%
- Price
- $3.56
- Shares after
- 320,446
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.
SEC remarks
Senior Vice President, Global Development and Medical Affairs